View Older Stories View More Recent Stories

Aug 16, 2017 01:22PM President Trump Announces End of Strategic & Policy Forum and Manufacturing Council on Twitter
Aug 14, 2017 05:11AM Trump yields to pressure, calls neo-Nazis and KKK criminals
Jul 28, 2017 06:45AM Merck Announces Second-Quarter 2017 Financial Results
Jul 27, 2017 09:26AM Pre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
Jul 27, 2017 09:00AM Mandy Moore and Merck Encourage Women to Plan Ahead in Her Life. Her Adventures. Campaign
Jul 27, 2017 06:45AM REPEAT/AstraZeneca and Merck Establish Strategic Oncology Collaboration
Jul 27, 2017 02:12AM AstraZeneca and Merck Establish Strategic Oncology Collaboration
Jul 25, 2017 03:57PM Merck Announces Fourth-Quarter 2017 Dividend
Jul 25, 2017 08:37AM Merck (MRK) Announces Doravirine Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection
Jul 25, 2017 08:35AM Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatme
Jul 24, 2017 05:04PM Merck (MRK) Says Phase 3 Study of KEYTRUDA Monotherapy in Patients with Previously Treated Recurrent or Metastatic HNSCC Didn't Meet Primary Endpoint
Jul 24, 2017 05:00PM Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Jul 24, 2017 08:05AM Merck (MRK) Announces U.S. Launch of RENFLEXIS
Jul 24, 2017 08:00AM Merck Announces U.S. Launch of RENFLEXIS™ (infliximab-abda), a Biosimilar of Remicade, for All Eligible Indications
Jul 24, 2017 07:05AM Merck (MRK) Announces Week 96 Results from ONCEMRK Study Evaluating ISENTRESS HD
Jul 24, 2017 07:00AM Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS® HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appro
Jul 21, 2017 07:50AM EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Jul 21, 2017 07:34AM Merck (MRK) Announces EMA's CHMP Recommends Approval for KEYTRUDA for Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Jul 21, 2017 07:31AM European Medicines Agency’s CHMP Recommends Approval for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type o
Jul 20, 2017 03:18PM Merck (MRK) and Pfizer (PFE) Collaborate with Corning (GLW) to Modernize Pharmaceutical Glass Packaging
Jul 20, 2017 03:15PM Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging
Jul 20, 2017 07:34AM Merck (MRK) Granted Tentative Approval for LUSDUNA Nexvue (insulin glargine injection)
Jul 20, 2017 07:30AM Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue™ (insulin glargine injection), a Follow-On Biologic Basal Insulin
Jul 17, 2017 07:07AM Merck (MRK) Announces Presentations of Clinical and Real-World Data AAIC
Jul 17, 2017 07:00AM Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer’s Association International Conference®
Jul 6, 2017 05:45PM Merck to Hold Second-Quarter 2017 Sales and Earnings Conference Call on July 28
Jul 6, 2017 07:00AM Merck to Present New Data from Clinical Trials Evaluating ISENTRESS® HD (raltegravir) and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017
Jul 5, 2017 04:31PM Merck (MRK) Says Three Multiple Myeloma Studies Evaluating KEYTRUDA Placed on Hold After More Deaths
Jul 5, 2017 04:30PM Merck Provides Further Update on Three Multiple Myeloma Studies Evaluating KEYTRUDA® (pembrolizumab) in Combination with Pomalidomide or Lenalidomide
Jun 27, 2017 11:25AM UPDATE: Merck (MRK) Confirms Computer Network Compromised
Jun 27, 2017 06:56AM Merck (MRK) REVEAL Study of Anacetrapib Met Primary Endpoint of Reducing Major Coronary Events
Jun 27, 2017 06:55AM Merck Provides Update on REVEAL Outcomes Study of Anacetrapib
Jun 22, 2017 08:52AM Merck (MRK), Premier (PINC) Expand Pact to Address Chronic Care and Vaccination Rates
Jun 22, 2017 08:48AM Merck and Premier Inc. Expand Collaboration to Address Chronic Care and Vaccination Rates
Jun 12, 2017 04:16PM Merck (MRK) Presents Update on Multiple Myeloma Studies KEYNOTE-183 & 185 of KEYTRUDA (pembrolizumab) in Combination with Other Therapies
Jun 12, 2017 04:15PM Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies
Jun 10, 2017 01:00PM Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies
Jun 5, 2017 07:33AM Merck (MRK) Says Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of KEYTRUDA Compared to Chemotherapy in Treatment of Patients with NSCLC with High Levels of PD-L1
Jun 5, 2017 07:30AM Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck’s KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small
Jun 5, 2017 07:08AM Merck (MRK) Presents New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of KEYTRUDA (pembrolizumab) Plus Standard Neoadjuvant Therapy
Jun 5, 2017 07:05AM Incyte (INCY), Merck (MRK) Provide Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA
Jun 5, 2017 07:05AM New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer
Jun 5, 2017 07:00AM Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types
Jun 5, 2017 06:43AM Merck (MRK) Reports 1+ Year Follow-Up on KEYTRUDA (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy
Jun 5, 2017 06:41AM Merck (MRK) Announces New Monotherapy Data for KEYTRUDA (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer
Jun 5, 2017 05:48AM Merck (MRK) Reports New Data on Response for Merck’s KEYTRUDA (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Jun 5, 2017 05:46AM Merck (MRK) Announces Follow-Up Data with Merck’s KEYTRUDA (pembrolizumab) in Combination with Pemetrexed & Carboplatin at ASCO Meetings
Jun 4, 2017 10:00AM New Monotherapy Data for Merck’s KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting
Jun 4, 2017 09:00AM With More than One-Year Follow-Up, Merck’s KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients P
Jun 3, 2017 09:00AM Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
View More Recent Stories View Older Stories